Rexahn Completes Patient Enrollment in Serdaxin(TM) Phase IIa Clinical Trial for Depression Jul 7, 2009
Rexahn Pharmaceuticals Signs Development and Commercialization Agreement with a Top 20 Pharmaceutical Company for Novel Anti-cancer Compound Jun 29, 2009
New Animal Study of Rexahn's Serdaxin(TM) Shows Drug's Promise to Treat Anxiety and Depression with Minimal Side Effects Jun 15, 2009
Rexahn Pharmaceuticals Announces Registered Direct Offering of up to $10 Million of Common Stock and Warrants May 20, 2009
Rexahn Achieves 50% Enrollment Milestone in Serdaxin(TM) Phase IIa Clinical Trial for Depression May 18, 2009